Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Ho: Ibalizumab for HIV Prevention |
| Strategy: | Prophylactic neutralizing Ab |
| Study Type: | Antibody Screening |
| Species: | Non-Organism Study |
| Stage: | Assays Completed |
| Study Start Date: | 2011-08-31 |
| Study Made Public: | 2013-02-08 |
Title
In vitro neutralization activity of a glycan-modified ibalizumab variant
Description
CAVD 272 is an immunogenicity study to evaluate the in vitro neutralization activity of Glyco iMab, a glycan-modified Ibalizumab variant.
Sign in to see full information about this study and to download study data.
Products
Glyco iMabIntegrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.